摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(三氟甲基)苯乙醇 | 455-01-6

中文名称
3-(三氟甲基)苯乙醇
中文别名
间三氟甲基苯乙醇
英文名称
2-[3-(trifluoromethyl)phenyl]ethanol
英文别名
2-(3-(trifluoromethyl)phenyl)ethan-1-ol;3-(trifluoromethyl)phenethyl alcohol;2-(3-(Trifluoromethyl)phenyl)ethanol
3-(三氟甲基)苯乙醇化学式
CAS
455-01-6
化学式
C9H9F3O
mdl
MFCD00009710
分子量
190.165
InChiKey
YDKIPCCKZKQMDT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    102 °C/12 mmHg (lit.)
  • 密度:
    1.261 g/mL at 25 °C (lit.)
  • 闪点:
    185 °F
  • 保留指数:
    1151
  • 稳定性/保质期:
    按规格使用和贮存,不会发生分解,避免与氧化物接触。

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.333
  • 拓扑面积:
    20.2
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 危险品标志:
    Xi
  • 安全说明:
    S26,S36/37/39
  • 危险类别码:
    R36/37/38
  • WGK Germany:
    3
  • 海关编码:
    2906299090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    密封保存,并置于通风、干燥的地方,避免与其它氧化物接触。

SDS

SDS:de7d1e71fd3fef22c966802aaf20967c
查看

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 3-(Trifluoromethyl)phenethyl alcohol
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 455-01-6
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances



SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Skin irritation (Category 2), H315
Eye irritation (Category 2), H319
Specific target organ toxicity - single exposure (Category 3), H335
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xi Irritant R36/37/38
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards - none

SECTION 3: Composition/information on ingredients
Substances
Formula : C9H9F3O
Molecular Weight : 190,16 g/mol
CAS-No. : 455-01-6
EC-No. : 207-233-9
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
3-(Trifluoromethyl)phenethylic alcohol
CAS-No. 455-01-6 Skin Irrit. 2; Eye Irrit. 2; STOT <= 100 %
EC-No. 207-233-9 SE 3; H315, H319, H335
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
3-(Trifluoromethyl)phenethylic alcohol
CAS-No. 455-01-6 Xi, R36/37/38 <= 100 %
EC-No. 207-233-9
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with
water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
For small (incipient) fires, use media such as "alcohol" foam, dry chemical, or carbon dioxide. For large
fires, apply water from as far as possible. Use very large quantities (flooding) of water applied as a mist or
spray; solid streams of water may be ineffective. Cool all affected containers with flooding quantities of
water.
Special hazards arising from the substance or mixture
Carbon oxides, Hydrogen fluoride
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
Use water spray to cool unopened containers.

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid breathing vapours, mist or gas. Ensure adequate ventilation.
Remove all sources of ignition. Evacuate personnel to safe areas. Beware of vapours accumulating to
form explosive concentrations. Vapours can accumulate in low areas.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Contain spillage, and then collect with an electrically protected vacuum cleaner or by wet-brushing and
place in container for disposal according to local regulations (see section 13). Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
Keep away from sources of ignition - No smoking.Take measures to prevent the build up of electrostatic
charge.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Containers which are
opened must be carefully resealed and kept upright to prevent leakage.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
impervious clothing, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator
with multi-purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup
to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air
respirator. Use respirators and components tested and approved under appropriate government
standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: liquid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and 102 °C at 16 hPa - lit.
boiling range
g) Flash point 85 °C - closed cup
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density 1,261 g/cm3 at 25 °C
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
Heat, flames and sparks.
Incompatible materials
Oxidizing agents, Reducing agents, Acid chlorides, Acid anhydrides
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

SECTION 13: Disposal considerations
Waste treatment methods
Product
This combustible material may be burned in a chemical incinerator equipped with an afterburner and
scrubber. Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material.
Contaminated packaging
Dispose of as unused product.

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Eye Irrit. Eye irritation
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Skin Irrit. Skin irritation
STOT SE Specific target organ toxicity - single exposure
Full text of R-phrases referred to under sections 2 and 3
Xi Irritant
R36/37/38 Irritating to eyes, respiratory system and skin.
Further information
Copyright 2013 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

制备方法与用途

合成制备方法

暂无相关信息。

用途

暂无相关信息。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-(三氟甲基)苯乙醇戴斯-马丁氧化剂 作用下, 以 二氯甲烷 为溶剂, 反应 3.0h, 生成 2-(3-(三氟甲基)苯基)乙醛
    参考文献:
    名称:
    [EN] PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE
    [FR] PIPÉRIDINE-2,6-DIONES UTILISÉES COMME AGENTS DE DÉGRADATION À PETITES MOLÉCULES D'HÉLIOS ET MÉTHODES D'UTILISATION
    摘要:
    本文披露了一些化合物及其药用盐、水合物、溶剂合物、前药、立体异构体和互变异构体,这些化合物可能导致各种蛋白质的降解,例如IKZF2(Helios)。同时还披露了含有这些化合物的药物组合物,以及使用这些化合物治疗与Helios相关的疾病和障碍,并可能从Helios降解中受益的方法。
    公开号:
    WO2021236885A1
  • 作为产物:
    描述:
    3-三氟甲基苯乙酸甲酯三乙基硼氢化钠 、 sodium hydroxide 作用下, 以 乙醚甲苯甲醇 为溶剂, 反应 10.0h, 以95%的产率得到3-(三氟甲基)苯乙醇
    参考文献:
    名称:
    一般实用的三乙基硼烷催化的羰基官能团还原为醇
    摘要:
    大量廉价的三乙基硼烷与烷醇钠的组合可生成一种高效催化剂,用于在温和条件下使用廉价的氢化硅烷将酯以及酮和醛还原为醇。该催化剂体系表现出优异的化学选择性和高水平的官能团耐受性。机理研究表明,三乙基烷氧基棉酸钠的静置状态是BEt 3与醇钠反应的产物。该硼酸盐物质与氢硅烷反应形成NaBEt 3 H,这会迅速还原酯。
    DOI:
    10.1002/chem.201502942
点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED BENZAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE BENZAMIDE SUBSTITUÉS
    申请人:HOFFMANN LA ROCHE
    公开号:WO2011076678A1
    公开(公告)日:2011-06-30
    The invention relates to compounds of formula I wherein R is hydrogen or lower alkyl; R1 is -(CH2)n-(O)o-heterocycloalkyl or -C(O)-heterocycloalkyl, wherein the heterocycloalkyl group is optionally substituted by lower alkyl, hydroxy, halogen or by -(CH2)p-aryl; n is 0, 1 or 2; o is 0 or 1; p is 0, 1 or 2; R2 is CF3, cycloalkyl, optionally substituted by lower alkoxy or halogen, or is indan-2-yl, or is heterocycloalkyl, optionally substituted by heteroaryl, or is aryl or heteroaryl, wherein the aromatic rings are optionally substituted by one or two substituents, selected from lower alkyl, halogen, heteroaryl, hydroxy, CF3, OCF3, OCH2CF3, OCH2-cycloalkyl, OCH2C(CH2OH)(CH2C1)(CH3), S-lower alkyl, lower alkoxy, CH2-lower alkoxy, lower alkinyl or cyano, or by-C(O)-phenyl, -O-phenyl, -O- CH2-phenyl, phenyl or -CH2-phenyl, and wherein the phenyl rings may optionally be substituted by halogen, -C(O)-lower alkyl, -C(O)OH or -C(O)O-lower alkyl, or the aromatic rings are optionally substituted by heterocycloalkyl, OCH2-oxetan-3-yl or O-tetrahydropyran-4-yl, optionally substituted by lower alkyl; X is a bond, -NR'-, -CH2NH-, -CHR''-, -(CHR'')q-O-, -O-(CHR'')q- or -(CH2)2-; Y is a bond or -CH2- R' is hydrogen or lower alkyl, R'' is hydrogen, lower alkyl, CF3, lower alkoxy, q is 0, 1, 2 or 3; or to a pharmaceutically suitable acid addition salt thereof. It has now been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinsons disease, neurodegenerative disorders such as Alzheimers disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
    该发明涉及以下式I的化合物,其中R是氢或较低的烷基;R1是-(CH2)n-(O)o-杂环烷基或-C(O)-杂环烷基,其中杂环烷基基团可选择地被较低的烷基,羟基,卤素或-(CH2)p-芳基取代;n为0、1或2;o为0或1;p为0、1或2;R2为CF3,环烷基,可选择地被较低的烷氧基或卤素取代,或为茚-2-基,或为杂环烷基,可选择地被杂芳基取代,或为芳基或杂芳基,其中芳香环可选择地被来自较低的烷基,卤素,杂芳基,羟基,CF3,OCF3,OCH2CF3,OCH2-环烷基,OCH2C(CH2OH)(CH2C1)(CH3),S-较低的烷基,较低的烷氧基,CH2-较低的烷氧基,较低的炔基或氰基,或-C(O)-苯基,-O-苯基,-O-CH2-苯基,苯基或-CH2-苯基选择的一个或两个取代基取代,其中苯环可选择地被卤素,-C(O)-较低的烷基,-C(O)OH或-C(O)O-较低的烷基取代,或芳香环可选择地被杂环烷基,OCH2-氧杂环戊烷-3-基或O-四氢吡喃-4-基,可选择地被较低的烷基取代;X为键,-NR'-,-CH2NH-,-CHR''-,-(CHR'')q-O-,-O-(CHR'')q-或-(CH2)2-;Y为键或-CH2-;R'为氢或较低的烷基,R''为氢,较低的烷基,CF3,较低的烷氧基,q为0、1、2或3;或其药学上适宜的酸盐。现已发现,该式I的化合物对痕量胺相关受体(TAARs)具有良好的亲和力,特别是对于TAAR1。这些化合物可用于治疗抑郁症,焦虑症,躁郁症,注意力缺陷多动障碍(ADHD),与压力有关的疾病,如精神分裂症,帕金森病等神经疾病,阿尔茨海默病等神经退行性疾病,癫痫,偏头痛,高血压,物质滥用和代谢性疾病,如进食障碍,糖尿病,糖尿病并发症,肥胖症,血脂异常,能量消耗和吸收异常,体温稳态异常,睡眠和昼夜节律异常,以及心血管疾病。
  • Visible Light-Induced α-C(sp<sup>3</sup>)–H Acetalization of Saturated Heterocycles Catalyzed by a Dimeric Gold Complex
    作者:Xiaojia Si、Lumin Zhang、Zuozuo Wu、Matthias Rudolph、Abdullah M. Asiri、A. Stephen K. Hashmi
    DOI:10.1021/acs.orglett.0c01924
    日期:2020.8.7
    situ-formed gold complex. The broad functional group compatibility and substrate scope indicate that our strategy is a promising way to synthesize acetal analogues. The method was successfully applied in late-stage modifications of bioactive molecules. Gram scale syntheses and mechanistic studies are also presented.
    饱和杂环缩醛是有机合成和其他领域的有用片段。本文中,使用碘代苯和原位形成的金络合物在可见光照射下实现了醚,四氢噻吩和吡咯烷的C(sp 3)–H脱氢交叉偶联。广泛的官能团相容性和底物范围表明,我们的策略是合成缩醛类似物的一种有前途的方法。该方法已成功应用于生物活性分子的后期修饰。还介绍了革兰氏鳞片的合成和机理研究。
  • Novel 4-phenylpiperidines for the treatment of pruritic dermatoses
    申请人:——
    公开号:US20030078282A1
    公开(公告)日:2003-04-24
    Novel compounds having general formula (I), and pharmaceutically and veterinarily acceptable salts thereof wherein R 1, R 2, R 3, W, Y 1, Y 2, X, n and y are as defined above and processes for their preparation and intermediate compounds prepared therein. The novel compounds are useful for having utility in the treatment. of pruritic dermatoses including allergic dermatitis and atopy in animals and humans
    具有通用公式(I)的新化合物,以及药物和兽药可接受的盐,其中R 1、R 2、R 3、W、Y 1、Y 2、X、n和y如上所述定义,以及它们的制备过程和其中制备的中间化合物。这些新化合物在治疗包括动物和人类的瘙痒性皮肤病,包括过敏性皮炎和异位症方面具有用途。
  • SUBSTITUTED BENZAMIDES
    申请人:Groebke Zbinden Katrin
    公开号:US20110152245A1
    公开(公告)日:2011-06-23
    The invention relates to compounds of formula wherein R, R 1 , R 2 , X, and Y are as defined herein and to a pharmaceutically suitable acid addition salt thereof. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
    该发明涉及以下式的化合物 其中R、R1、R2、X和Y如本文所定义,并且其药学上适宜的酸盐。 式I的化合物对痕量胺相关受体(TAARs)具有良好的亲和力,特别是对TAAR1。这些化合物可用于治疗抑郁症、焦虑障碍、双相情感障碍、注意缺陷多动障碍(ADHD)、与压力有关的障碍、如精神分裂症的精神障碍、如帕金森病的神经疾病、如阿尔茨海默病的神经退行性疾病、癫痫、偏头痛、高血压、物质滥用和代谢性障碍,如进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍,以及心血管疾病。
  • An asymmetric Salamo-based Zn complex supported on Fe<sub>3</sub>O<sub>4</sub> MNPs: a novel heterogeneous nanocatalyst for the silyl protection and deprotection of alcohols under mild conditions
    作者:Hongyan Yao、Yongsheng Wang、Maryam Kargar Razi
    DOI:10.1039/d1ra01185e
    日期:——
    Fe3O4@H2L-Zn MNPs as a magnetically separable, recyclable and reusable heterogeneous catalyst. Fe3O4@H2L-Zn MNPs were also applied for the removal of silyl protecting groups from hydroxyl functions using water in CH2Cl2 under green conditions. The catalyst demonstrated good to excellent catalytic yield efficiency for both the reactions compared to the commercial metal-based catalysts under green conditions for
    在本研究中,磁性不对称 Salamo 基 Zn 配合物(H 2 L = salen 型二希夫碱)负载在改性 Fe 3 O 4 (Fe 3 O 4 @H 2 L-Zn) 的表面上作为一种新的磁性材料。催化剂通过多种分析技术进行设计和表征,例如 FT-IR 光谱、XRD、EDS、ICP-AES、SEM、TEM、TGA 和 VSM。提出了一种有效且可持续的合成方案,用于在温和条件下通过醇的甲硅烷基保护合成甲硅烷基醚子结构。该合成方案涉及各种含羟基底物和作为廉价甲硅烷基化剂的六甲基二硅氮烷(HMDS)之间的双组分无溶剂反应,使用Fe 3 O 4 @H 2 L-Zn MNP作为磁性可分离、可回收和可重复使用的多相催化剂。 Fe 3 O 4 @H 2 L-Zn MNP 也可用于在绿色条件下使用 CH 2 Cl 2中的水从羟基官能团中去除甲硅烷基保护基团。与商业金属基催化剂相比,该催化剂在绿色条件下对多种底物表现出良好至优异的催化产率。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
mass
cnmr
ir
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐